Corcept Therapeutics Property Plant And Equipment Net Over Time

CORT Stock  USD 52.42  2.72  4.93%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Corcept Therapeutics Performance and Corcept Therapeutics Correlation.
  
Property Plant And Equipment Net is likely to gain to about 559.2 K in 2024.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.464
Earnings Share
1.26
Revenue Per Share
6.107
Quarterly Revenue Growth
0.477
Return On Assets
0.13
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Property Plant And Equipment Net Analysis

Compare Corcept Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Property Plant And Equipment Net Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
IDYA3.7 M3.7 M3.7 M3.7 M3.7 M3.7 M3.7 M3.7 M5.2 M9.7 M9.5 M8.7 MM8.4 M8.5 M
ANAB750 K750 K750 K750 K579 K551 K471 K665 K1.4 M1.6 M1.8 M21.8 M20 M18.3 M19.2 M
MGTXMMMMMMM14.3 M22 M52.9 M87.1 M126.3 M154.1 M156.2 M84.7 M
KROS1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.4 M1.9 M1.6 M2.4 M17.6 M19.5 M20.4 M
EWTX498 K498 K498 K498 K498 K498 K498 K498 K498 K498 K516 K912 K9.9 M12.7 M13.3 M
GLUE1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M1.3 M4.6 M12.3 M61.9 M62.6 M31.4 M
ERAS4.3 M4.3 M4.3 M4.3 M4.3 M4.3 M4.3 M4.3 M4.3 M4.3 M4.1 M33.3 M65.2 M60.2 M36.8 M
HALO235.5 K1.8 M3.7 M3.4 MM3.9 M4.3 M3.5 M7.5 M10.9 M10.6 M8.8 M75.6 M74.9 M78.7 M
AGIO3.2 M3.2 M3.6 M3.8 M6.4 M23.2 M25.3 M24.4 M24.3 M126.1 M117.5 M104.2 M88.1 M69.8 M52.5 M
INSM241.4 K1.9 M1.7 M1.8 M7.5 M8.1 M10 M12.4 M22.6 M113.1 M97.2 M95.5 M102.1 M104.4 M109.6 M
RARE759 K759 K1.4 M1.3 MM7.4 M17.1 M21.8 M20 M74.7 M114 M176.2 M285.7 M290.6 M305.1 M
CYTK9.7 M1.3 M997 K1.2 M1.6 M1.8 M3.6 M3.6 M3.2 M13.4 M22.6 M146.4 M163.2 M147.7 M155.1 M
DYN10.7 B3.3 BB3.3 B3.3 B8.3 B7.1 B8.9 B110 K1.5 M1.9 M41 M38.4 M33.4 M31.7 M
SNSE123 K123 K123 K123 K123 K123 K123 K123 K123 K268 K1.3 M4.6 M9.7 MM4.2 M
NXTC10 M10 M10 M10 M10 M10 M10 M10 M11.4 M12.1 M15.8 M14 M16.9 M13.4 M14.7 M
NUVB646 K646 K646 K646 K646 K646 K646 K646 K646 K646 K688 K3.7 M4.7 M4.3 M3.1 M

Corcept Therapeutics and related stocks such as Ideaya Biosciences, AnaptysBio, and MeiraGTx Holdings PLC Property Plant And Equipment Net description

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

My Equities

My Current Equities and Potential Positions

Corcept Therapeutics Incorporated
CORT
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 52.42

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.